malignancies – Page 3 – Communicable Diseases Research

Risk and Outcome of Breakthrough COVID-19 Infections in Vaccinated Patients With Cancer: Real-World Evidence From the National COVID Cohort Collaborative

백신 접종을 받은 암 환자의 획기적인 COVID-19 감염의 위험과 결과: 국가 COVID 코호트 협력의 실제 증거

Article

Published on 2022-05-012022-09-11
Journal: Journal of clinical oncology : official journal of [Category] COVID19(2023년), SARS, 변종,

[키워드] 95% CI adjusted age analyzed BNT162b2 BNT162b2 vaccine Bone marrow Bone marrow transplantation booster Breakthrough infection breakthrough infections Cancer cancers Cohort controls COVID COVID-19 COVID-19 case COVID-19 cases COVID-19 infection COVID-19 infections Evidence hematologic Hematologic malignancy higher risk identify immunosuppressive effect increased risk leukemia Logistic regression lymphoid lymphoma malignancies medications Moderna mRNA COVID-19 vaccine mRNA COVID-19 vaccines mRNA-1273 Multiple myeloma Myeloma National new SARS-CoV-2 Odds ratios outcome outcomes Patient patients Patients with cancer Pfizer ranged risk SARS-COV-2 infection SARS-CoV-2 variants Sex significantly higher smoking smoking status Solid solid tumors Tumor tumors vaccination Vaccine vaccine dose variants was reduced
[DOI] 10.1200/JCO.21.02419 PMC 바로가기 [Article Type] Article

The effect of a third-dose BNT162b2 vaccine on anti-SARS-CoV-2 antibody levels in immunosuppressed patients

면역 억제 환자의 항 SARS-CoV-2 항체 수준에 대한 3차 접종 BNT162b2 백신의 효과

Observational Study

Published on 2022-05-012022-09-12
Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), MERS, SARS, 임상, 진단,

[키워드] 95% CI acute respiratory syndrome Administered anti-SARS-CoV-2 antibody antibody Antibody Response baseline BNT162b2 BNT162b2 vaccine booster booster dose Booster vaccine clinical outcomes Cohort cohorts coronavirus coronavirus disease COVID-19 disease Diseases dose entire cohort evaluate expressed Fold change haematologic highest hospital IgG antibody immunogenic Immunosuppressed immunosuppressed patient Immunosuppression increase in individuals interquartile range IQR Level malignancies Observational cohort study of BNT162b2 Patient patients Pfizer-BioNTech mRNA vaccine recipients rheumatology SARS-CoV-2 seroconversion rate seronegative seropositive significantly spike receptor-binding domain the median Transplant vaccination Vaccine were measured
[DOI] 10.1016/j.cmi.2022.02.002 PMC 바로가기 [Article Type] Observational Study

Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis

혈액암 환자에서 코로나19 백신의 면역원성: 체계적 고찰 및 메타분석

Meta-Analysis

Published on 2022-04-122022-09-12
Journal: Blood advances [Category] COVID19(2023년), SARS, 진단,

[키워드] active treatment adverse event Analysis approach cellular response Cellular responses clinical study Cochrane Central conducted Confidence intervals COVID-19 infection COVID-19 vaccination COVID-19 vaccine disease dose doses expressed first dose healthy control hematologic highest immune response immunogenicity leukemia lowest malignancies malignancy Meta-analysis monoclonal antibody morbidity and mortality Neutralizing antibodies Neutralizing antibody response New Odds ratio outcome Patient patient group positive random effect Rate reduce required respond poorly second dose Secondary outcomes single-arm study stratified systematic review therapy Treatment
[DOI] 10.1182/bloodadvances.2021006333 PMC 바로가기 [Article Type] Meta-Analysis

Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination

SARS-CoV-2 예방접종 후 혈액암 환자의 혈청전환율에 대한 치료의 영향

Meta-Analysis

Published on 2022-04-052022-09-12
Journal: The oncologist [Category] COVID19(2023년), SARS, 진단,

[키워드] 95% confidence interval acute respiratory syndrome Anti-CD20 antibody antibody ARMS article chronic CLL CLL patient conducted Control coronavirus COVID-19 database determinants Efficacy first dose group healthy control hematologic Hematologic malignancy hematological Hematological malignancies Hematological malignancy Impact kinase literature review malignancies Meta-analysis organization Patient patient population patients treated Rate remained review risk SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine second dose seroconversion rate significant difference significantly lower subject subjects the antibody response treated vaccination Vaccine
[DOI] 10.1093/oncolo/oyac032 PMC 바로가기 [Article Type] Meta-Analysis

Do reduced numbers of plasmacytoid dendritic cells contribute to the aggressive clinical course of COVID-19 in chronic lymphocytic leukaemia?

감소된 수의 형질세포양 수지상 세포가 만성 림프구성 백혈병에서 COVID-19의 공격적인 임상 경과에 기여합니까?

Review

Published on 2022-04-012022-09-11
Journal: Scandinavian journal of immunology [Category] COVID19(2023년), SARS, 유전자 메커니즘,

COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA

Clinical Trial

Published on 2022-03-102022-10-05
Journal: Blood [Category] SARS, 임상,

Emergency Use and Efficacy of an Asynchronous Teledermatology System as a Novel Tool for Early Diagnosis of Skin Cancer during the First Wave of COVID-19 Pandemic

COVID-19 팬데믹의 첫 번째 물결 동안 피부암의 조기 진단을 위한 새로운 도구로서 비동기식 원격 피부과 시스템의 긴급 사용 및 효능

Article

Published on 2022-02-252022-09-10
Journal: International Journal of Environmental Research an [Category] COVID19(2023년), MERS, SARS, 치료기술,

COVID-19 in children with haematological malignancies

Short Report

Published on 2022-02-222022-10-28
Journal: Archives of Disease in Childhood [Category] COVID-19, COVID19(2023년), Fulltext, MERS, SARS,

Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies

Article

Published on 2022-02-142022-10-04
Journal: Nature Communications [Category] COVID19(2023년), MERS, SARS, 진단,

[키워드] anti-S antibodies B cell BNT162b2 boost cellular immunity cellular response Cohort dose effective fraction Haematological cancer Hematological malignancy Humoral immunity IFN-γ immune response immune stimulation increase independent induce leukemia lymphoid malignancies malignancy MONITOR mRNA vaccine Multiple myeloma neutralizing antibody Neutralizing antibody titer Non-Hodgkin Lymphoma of BNT162b2 Patient Pfizer/BioNTech positive reported response RNA vaccines SARS-CoV-2 SARS-CoV-2 BNT162b2 secretion seronegative patient seronegative patients severe COVID-19 symptoms Side effect Support T-cell Response the median vaccination Vaccine vaccine dose
[DOI] 10.1038/s41467-022-28578-0 PMC 바로가기 [Article Type] Article

Cytokines and Chemokines in Cancer Cachexia and Its Long-Term Impact on COVID-19

Review

Published on 2022-02-082022-10-31
Journal: Cells [Category] COVID-19, COVID19(2023년), MERS, SARS,